BRAF and neoplasm: Importantly, AP2 gene expression lacked any strong association with cancer staging in BRAF mutated RAI-treated PTC (Supp Fig. S5D-S5F), suggesting that the predictive value was likely related to a poorer response to RAI therapy, in addition to any potential impact on tumour aggressive features.